{
    "clinical_study": {
        "@rank": "26917", 
        "acronym": "HER3-Lung", 
        "arm_group": [
            {
                "arm_group_label": "Patritumab + erlotinib", 
                "arm_group_type": "Experimental", 
                "description": "Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks) and oral erlotinib 150 mg/day"
            }, 
            {
                "arm_group_label": "Placebo + erlotinib", 
                "arm_group_type": "Experimental", 
                "description": "Placebo infusion every 3 weeks and oral erlotinib 150 mg/day"
            }
        ], 
        "brief_summary": {
            "textblock": "1. Part A: Subjects will receive Patritumab or placebo with erlotinib. Progression-free\n           survival will be the primary outcome. Subjects will need to have Epidermal Growth\n           Factor Receptor (EGFR) wild-type, locally advance or metastatic NSCLC and have their\n           cancer progressed after at least one prior systemic anti-cancer therapy, available\n           recent or archival tumor specimen and may not have had previous EGFR-targeted regimen,\n           anti-HER2 (Human Epidermal Growth Factor Receptor 2), anti-HER3, or anti-HER4 therapy.\n           Subjects may have high heregulin or low heregulin.\n\n        2. Part B: Subjects will receive Patritumab or placebo with erlotinib. Overall survival\n           will be the primary outcome. Subjects will need to have EGFR wild-type, locally advance\n           or metastatic NSCLC and have their cancer progressed after at least one prior systemic\n           anti-cancer therapy, available recent or archival tumor specimen and may not have had\n           previous EGFR-targeted regimen, anti-HER2, anti-HER3, or anti-HER4 therapy.  Only\n           subjects with high heregulin will be enrolled."
        }, 
        "brief_title": "Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)", 
        "completion_date": {
            "#text": "September 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Lung Cancer", 
            "Non Small Cell Lung Cancer."
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Must be greater or equal to 20 years of age\n\n          2. Must have histologically confirmed NSCLC with either:\n\n               -  Metastatic disease (Stage IV) OR\n\n               -  Stage IIIB disease not amenable to surgery or curative intent.\n\n          3. If tumor histology is adenocarcinoma, must have wild-type EGFR genotype as assessed\n             by a validated assay that includes exon 19 deletion and exon 21 (L858R) substitution.\n\n          4. Must have received one or two prior lines of systemic anti-cancer therapy for\n             advanced or metastatic disease, one of which must be a platinum-doublet therapy.\n\n          5. Must have disease progression or recurrence documented by radiographic assessment\n             following treatment after last chemotherapy or chemoradiation regimen (completed\n             within the previous 12 months).\n\n          6. Must have available recent (before treatment start) or archival tumor specimen.\n\n          7. Must have measurable disease for Part A, measurable disease or non-measurable disease\n             for Part B\n\n          8. Must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          9. Must have adequate hematological function\n\n         10. Must have adequate renal function\n\n         11. Must have adequate hepatic function\n\n         12. Agreement to use effective contraception while on treatment and for at least 6 months\n             after end of treatment\n\n         13. Must have provided informed consent for study participation.\n\n        Exclusion Criteria:\n\n          1. Lung adenocarcinoma with an Anaplastic Lymphoma Kinase (ALK) gene rearrangement\n\n          2. Left ventricular ejection fraction (LVEF) less than 45%\n\n          3. Prior EGFR-targeted regimen, anti-HER2, anti-HER3, or anti-HER4 therapy\n\n          4. History of other malignancies, except adequately treated non-melanoma skin cancer,\n             curatively treated in-situ disease, or other solid tumors curatively treated with no\n             evidence of disease for greater or equal to 5 years\n\n          5. History of corneal disease\n\n          6. History of interstitial lung disease (ILD)\n\n          7. Clinically active brain metastases\n\n          8. Uncontrolled hypertension\n\n          9. Clinically significant ECG changes\n\n         10. Clinically significant (any grade) ascites or pleural effusion requiring chronic\n             medical intervention\n\n         11. Myocardial infarction within 1 year before enrollment, symptomatic congestive heart\n             failure, unstable angina, or unstable cardiac arrhythmia requiring medication\n\n         12. Treatment with anticancer therapy, antibody-based therapy, retinoid therapy, or\n             hormonal therapy within 4 weeks before study drug treatment\n\n         13. Therapeutic radiation therapy or major surgery within 4 weeks before study drug\n             treatment; or palliative radiation within 2 weeks before study drug treatment\n\n         14. Participation in clinical drug trials within 4 weeks\n\n         15. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals, known\n             human immunodeficiency virus (HIV) infection, or active hepatitis B or C infection.\n\n         16. History of hypersensitivity to any of the study drugs or to any excipients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "780", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02134015", 
            "org_study_id": "U31287-A-U301"
        }, 
        "intervention": [
            {
                "arm_group_label": "Patritumab + erlotinib", 
                "description": "Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)", 
                "intervention_name": "Patritumab", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Patritumab + erlotinib", 
                    "Placebo + erlotinib"
                ], 
                "description": "Oral erlotinib 150 mg/day.", 
                "intervention_name": "erlotinib:", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo + erlotinib", 
                "description": "Placebo infusion every 3 weeks", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Erlotinib", 
                "Molecular Mechanisms of Pharmacological Action"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Carcinoma", 
            "Non-Small-Cell Lung", 
            "Lung Neoplasms", 
            "Bronchogenic", 
            "Bronchial Neoplasms", 
            "Respiratory Tract Neoplasms", 
            "Thoracic Neoplasms", 
            "Neoplasms by Site", 
            "Neoplasms", 
            "Lung Diseases", 
            "Respiratory Tract Diseases", 
            "Erlotinib", 
            "Therapeutic Uses", 
            "Pharmacologic Actions", 
            "Molecular Mechanisms of Pharmacological Action"
        ], 
        "lastchanged_date": "May 13, 2014", 
        "location": [
            {
                "contact": {
                    "email": "fadi.braiteh@usoncology.com", 
                    "last_name": "Braiteh, MD", 
                    "phone": "702-952-3400"
                }, 
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Gandhi, MD", 
                    "phone": "423-622-2337"
                }, 
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "DeVore, MD", 
                    "phone": "865-934-2670"
                }, 
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "alexander.spira@usoncology.com", 
                    "last_name": "Spira, MD", 
                    "phone": "703-280-5390"
                }, 
                "facility": {
                    "address": {
                        "city": "Fairfax", 
                        "country": "United States", 
                        "state": "Virginia"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will be contacted every 12 weeks from date of randomization until date of death to track overall survival assessed up to 4 years.", 
            "measure": "Overall survival (OS) assessed every 12 weeks", 
            "safety_issue": "Yes", 
            "time_frame": "every 12 weeks from date of randomization until date of death"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02134015"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Patients will be evaluated for these endpoints every 6 weeks for the first 24 weeks after randomization and then every 12 weeks until date of death or up to 4 years.", 
            "measure": "Progression free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "every 6 weeks for the first 24 weeks after randomization and then every 12 weeks until date of death or up to 4 years"
        }, 
        "source": "Daiichi Sankyo Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Parexel", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Daiichi Sankyo Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}